Novogene describes the Pentagon’s move as factually flawed, emphasizing its status as an independent, publicly listed enterprise. The company maintains that it meets none of the statutory criteria for the list, specifically denying any beneficial ownership, control, or affiliation with military or intelligence organizations. Leadership has initiated a formal process to challenge the designation, signaling an intent to exhaust every available legal avenue to rectify the record.

Despite the friction with U.S. authorities, the firm reports that its global operations and client partnerships remain stable. Novogene continues to supply genomics services to universities, hospitals, and pharmaceutical companies worldwide. The company confirmed it remains fully committed to its existing research contracts and service agreements while it pursues a correction to the Department of Defense’s filing.